{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tsoulaki O"],"funding":["Cancer Research UK","National Institute for Health and Care Research Exeter Biomedical Research Centre","NIHR Cambridge Biomedical Research Centre","National Institute for Health Research (NIHR)"],"pagination":["2027-2036"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11183136"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["130(12)"],"pubmed_abstract":["<h4>Background</h4>The CanRisk tool, which operationalises the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is used by Clinical Geneticists, Genetic Counsellors, Breast Oncologists, Surgeons and Family History Nurses for breast cancer risk assessments both nationally and internationally. There are currently no guidelines with respect to the day-to-day clinical application of CanRisk and differing inputs to the model can result in different recommendations for practice.<h4>Methods</h4>To address this gap, the UK Cancer Genetics Group in collaboration with the Association of Breast Surgery and the CanGene-CanVar programme held a workshop on 16<sup>th</sup> of May 2023, with the aim of establishing best practice guidelines.<h4>Results</h4>Using "],"journal":["British journal of cancer"],"pubmed_title":["Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice."],"pmcid":["PMC11183136"],"funding_grant_id":["NIHR203312","C61296/A27223","PPRPGM-Nov20\\100002"],"pubmed_authors":["Tsoulaki O","Holcombe S","Gandhi A","Tischkowitz M","Hammond C","Antoniou AC","Kiesel V","Cutress R","Murray J","Archer S","Thorpe E","Cleaver R","Teh W","Turnbull C","Brennan P","Gilbert F","Fitzgerald S","Jewell R","Davidson R","Hayward J","Rea G","Wilkinson L","Searle C","Kemp Z","Hanson H","Howell A","Wilkinson S","Paramasivam A","Eccles D","Hawkes L","Whaite A","Binysh K","Bartlett M","Corbett G","Gold R","Shaw A","Speight B","Evers R","Hamilton S","Hutchison G","Ficorella L","Greville-Heygate S","Holliday D","Woodward ER","Nisbet S","Badran A","Sheridan E","Lalloo F","Youngs A","Jenkins J","Musgrave H","Meeting Attendees","Hart R","Ogunleye D","Berlin C","Andreou A","Smith K","Forman A","Kavanaugh G","Miedzybrodzka Z","Cox K","Irvine T","Side L","DeSouza B","Kumar A"],"additional_accession":[]},"is_claimable":false,"name":"Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.","description":"<h4>Background</h4>The CanRisk tool, which operationalises the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is used by Clinical Geneticists, Genetic Counsellors, Breast Oncologists, Surgeons and Family History Nurses for breast cancer risk assessments both nationally and internationally. There are currently no guidelines with respect to the day-to-day clinical application of CanRisk and differing inputs to the model can result in different recommendations for practice.<h4>Methods</h4>To address this gap, the UK Cancer Genetics Group in collaboration with the Association of Breast Surgery and the CanGene-CanVar programme held a workshop on 16<sup>th</sup> of May 2023, with the aim of establishing best practice guidelines.<h4>Results</h4>Using ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2025-04-04T12:47:41.832Z","creation":"2025-04-04T12:47:41.832Z"},"accession":"S-EPMC11183136","cross_references":{"pubmed":["38834743"],"doi":["10.1038/s41416-024-02733-4"]}}